Skip to main content

Table 3 Multivariable Cox regression analysis showing the associations of serum TSP2 level with incident HHF stratified by presence of CVD at baseline (N = 4949)

From: Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes

 

N

No. of incident HF (%)

Model 1

 

Model 2

 

Model 3

 

Adjusted HR for TSP2 (95% CI)

p-value

Adjusted HR for TSP2 (95% CI)

p-value

Adjusted HR for TSP2 (95% CI)

p-value

All

4949

330 (6.7)

1.27 (1.03–1.58)

0.028

1.29 (1.04–1.60)

0.020

1.31 (1.06–1.62)

0.014

No CVD at baseline

3335

178 (5.3)

1.12 (0.85–1.47)

0.424

1.15 (0.88–1.51)

0.318

1.18 (0.90–1.55)

0.235

CVD at baseline

1614

152 (9.4)

1.50 (1.06–2.13)

0.022

1.49 (1.04–2.14)

0.029

1.49 (1.04–2.13)

0.029

  1. *Log-transformed before analysis
  2. Model 1: Sex, age, duration of diabetes, ever smoker, BMI, systolic BP, dyslipidemia, atrial fibrillation, CVD, HbA1c, eGFR, albuminuria, and serum hsCRP levels at baseline
  3. Model 2: model 1 plus use of insulin, metformin, ACEI/ARB, beta-blockers, loop-diuretics and aspirin at baseline
  4. Model 3: model 2 plus time-dependent cumulative defined daily dose of SGLT2i.
  5. TSP2, thrombospondin 2; HHF, hospitalization for heart failure; HR, hazard ratio; 95%CI, 95% confidence interval; BMI, body mass index, BP, blood pressure; CVD, cardiovascular diseases; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; hsCRP, high sensitivity C-reactive protein; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; SGLT2i, sodium glucose co-transporter-2 inhibitors